![]() ![]() In December, Caribou provided positive updates on its cell therapy candidates. Bank of America has a “buy” rating and $112 price target for APLS stock.Ĭaribou Biosciences is a clinical-stage biotech company developing gene-edited cell therapies to treat cancer. Analyst Tazeen Ahmad says Syfovre’s GA approval is a “mic drop moment” for Apellis and projects $240 million in 2024 sales. Apellis is also collaborating with Beam Therapeutics to leverage base editing technology to research new precision therapies for the eye, liver and brain. In February 2023, the FDA also approved Syfovre as a treatment for geographic atrophy, or GA, which causes vision loss in old age. The company’s main product is Syfovre, which was approved by the FDA to treat paroxysmal nocturnal hemoglobinuria, a rare acquired blood disease. Bank of America has a “buy” rating and $60 price target for BEAM stock.Īpellis Pharmaceuticals is a biotech company focused on therapies targeting the complement pathway of the immune system, which enhances the immune system’s ability to clear damaged cells. In the meantime, he says the company’s $1.1 billion in cash and equivalents gives it a cash runway into at least 2025. Analyst Greg Harrison says Beam has an innovative technology platform and is on track for its first-in-human clinical data. The company focuses on blood and cancer indications but is also researching treatment for ocular and liver diseases. Bank of America has a “buy” rating and $116 price target for CRSP stock.īeam Therapeutics uses CRISPR technology to change single bases in the genome with a technique called base editing, which only breaks one strand of the DNA and may have higher cell survival rates. ![]() Analyst Geoff Meacham says CRISPR is one of his favorite biotech stocks of 2023 and says exa-cel creates a compelling risk-reward profile for investors. ( VRTX) expect the company’s gene-editing treatment exagamglogene autotemcel, or exa-cel, to get approval from the Food and Drug Administration to treat sickle cell disease and transfusion-dependent beta thalassemia in the near future. CRISPR and partner Vertex Pharmaceuticals Inc. Implied upside over March 9 closing priceĬRISPR Therapeutics is a biotech company that uses gene-editing tool CRISPR-Cas9 for blood disorders and cancer applications. Here are seven of the best gene-editing stocks to buy, according to Bank of America: Stock Most gene-editing stocks took a big hit in 2022, but analysts at Strategic Market Research expect the market to grow 17.3% annually and reach $21.4 billion by 2030. Gene editing takes the science to the next level, seeking to directly alter the genome itself as a therapeutic approach. Gene therapies can correct genetic abnormalities by introducing genetic material at a cellular level and can often take the form of adding a functioning copy of a gene. Gene therapy and gene editing are on the cutting edge of modern biotechnology. Business & Finance Click to expand menu. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |